New Cardiovascular Biomarkers in Ischemic Heart Disease-GDF-15, A Probable Predictor for Ejection Fraction.
ejection fraction
growth differentiation factor 15 (GDF-15)
heart failure
heart-type fatty acid-binding protein (H-FABP)
soluble suppression of tumorigenicity 2 (sST2)
soluble urokinase-type plasminogen activator receptor (suPAR)
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 Jun 2019
27 Jun 2019
Historique:
received:
12
06
2019
revised:
21
06
2019
accepted:
24
06
2019
entrez:
30
6
2019
pubmed:
30
6
2019
medline:
30
6
2019
Statut:
epublish
Résumé
Various biomarkers have been associated with coronary artery disease (CAD) and ischemic heart failure. The aim of this study was to investigate the correlation of serum levels of soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor 15 (GDF-15), heart-type fatty acid-binding protein (H-FABP), and soluble suppression of tumorigenicity 2 (sST2) with left ventricular ejection fraction (EF) in CAD patients and controls. CAD patients were divided into three groups according to their EF as measured by the biplane Simpson method (53-84%, 31-52%, ≤30%). Overall, 361 subjects were analyzed. In total, 155 CAD patients had an EF of 53-84%, 71 patients had an EF of 31-52%, and 23 patients had an EF of ≤30% as compared to 112 healthy controls (age 51.3 ± 9.0 years, 44.6% female). Mean ages according to EF were 62.1 ± 10.9, 65.2 ± 10.1, and 66.6 ± 8.2 years, respectively, with females representing 29.0, 29.6, and 13.0%. suPAR, GDF-15, H-FABP, and sST2 values were significantly higher in CAD patients and showed an exponential increase with decreasing EF. In a multiple logistic regression model, GDF-15 ( Biomarkers such as suPAR, GDF-15, H-FABP, and sST2 are increased in CAD patients, especially in highly impaired EF. Besides NT-proBNP as a well-known marker for risk prediction, GDF-15 may be an additional tool for diagnosis and clinical follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
Various biomarkers have been associated with coronary artery disease (CAD) and ischemic heart failure. The aim of this study was to investigate the correlation of serum levels of soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor 15 (GDF-15), heart-type fatty acid-binding protein (H-FABP), and soluble suppression of tumorigenicity 2 (sST2) with left ventricular ejection fraction (EF) in CAD patients and controls.
METHODS AND RESULTS
RESULTS
CAD patients were divided into three groups according to their EF as measured by the biplane Simpson method (53-84%, 31-52%, ≤30%). Overall, 361 subjects were analyzed. In total, 155 CAD patients had an EF of 53-84%, 71 patients had an EF of 31-52%, and 23 patients had an EF of ≤30% as compared to 112 healthy controls (age 51.3 ± 9.0 years, 44.6% female). Mean ages according to EF were 62.1 ± 10.9, 65.2 ± 10.1, and 66.6 ± 8.2 years, respectively, with females representing 29.0, 29.6, and 13.0%. suPAR, GDF-15, H-FABP, and sST2 values were significantly higher in CAD patients and showed an exponential increase with decreasing EF. In a multiple logistic regression model, GDF-15 (
CONCLUSION
CONCLUSIONS
Biomarkers such as suPAR, GDF-15, H-FABP, and sST2 are increased in CAD patients, especially in highly impaired EF. Besides NT-proBNP as a well-known marker for risk prediction, GDF-15 may be an additional tool for diagnosis and clinical follow-up.
Identifiants
pubmed: 31252588
pii: jcm8070924
doi: 10.3390/jcm8070924
pmc: PMC6678676
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical University of Vienna
ID : 1
Organisme : Paracelsus Medical University of Salzburg
ID : 1
Références
Hypertension. 2000 Feb;35(2):580-6
pubmed: 10679501
Circulation. 2003 Feb 11;107(5):721-6
pubmed: 12578875
Mol Cancer Ther. 2003 Oct;2(10):1023-9
pubmed: 14578467
Cell Tissue Res. 2004 Nov;318(2):325-33
pubmed: 15459768
Circ Res. 2006 Feb 17;98(3):351-60
pubmed: 16397141
Nat Rev Mol Cell Biol. 2007 Apr;8(4):275-83
pubmed: 17380161
J Am Coll Cardiol. 2007 Sep 11;50(11):1054-60
pubmed: 17825714
Clin Chem Lab Med. 2008;46(9):1313-8
pubmed: 18636795
Endocrinology. 2009 Apr;150(4):1688-96
pubmed: 19074584
Ann Clin Biochem. 2009 Nov;46(Pt 6):464-7
pubmed: 19564161
Clin Chim Acta. 2009 Nov;409(1-2):33-40
pubmed: 19699192
Circ Cardiovasc Genet. 2009 Jun;2(3):286-92
pubmed: 20031597
Circ Cardiovasc Genet. 2010 Feb;3(1):88-96
pubmed: 20160200
Circulation. 2010 Oct 5;122(14):1387-95
pubmed: 20855664
Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):203-10
pubmed: 20966402
Clin Chem. 2012 Jan;58(1):257-66
pubmed: 22096031
Clin Biochem Rev. 2012 Feb;33(1):3-11
pubmed: 22363093
Eur J Heart Fail. 2012 Nov;14(11):1249-56
pubmed: 22843564
Int J Cardiol. 2013 Sep 10;167(6):2904-11
pubmed: 22909410
Int J Cardiol. 2013 Oct 3;168(3):2186-94
pubmed: 23538053
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71
pubmed: 23684677
PLoS One. 2013 Jun 14;8(6):e65549
pubmed: 23799024
Am Heart J. 2014 Feb;167(2):186-192.e1
pubmed: 24439979
Eur J Heart Fail. 2014 Apr;16(4):377-83
pubmed: 24464777
J Biol Chem. 2014 Apr 4;289(14):10084-94
pubmed: 24554716
Circ Heart Fail. 2014 May;7(3):418-26
pubmed: 24622243
J Card Fail. 2014 Aug;20(8):569-76
pubmed: 24929121
Atherosclerosis. 2014 Nov;237(1):60-6
pubmed: 25222341
JACC Heart Fail. 2015 Jan;3(1):30-9
pubmed: 25447345
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Eur J Heart Fail. 2016 Jan;18(1):81-8
pubmed: 26497848
Nat Immunol. 2016 Feb;17(2):122-31
pubmed: 26784265
Emerg Med J. 2016 Nov;33(11):769-775
pubmed: 27590986
Clin Chem. 2017 Jan;63(1):140-151
pubmed: 28062617
JACC Heart Fail. 2017 Apr;5(4):268-277
pubmed: 28359415
Curr Atheroscler Rep. 2017 Jun;19(6):27
pubmed: 28432635
Mediators Inflamm. 2017;2017:9398401
pubmed: 28798540
J Am Heart Assoc. 2018 Jul 13;7(14):null
pubmed: 30006491
Med Sci Monit. 2018 Jul 18;24:4992-4999
pubmed: 30019695
Clin Chim Acta. 2018 Dec;487:48-53
pubmed: 30194932
J Investig Med. 2019 Jun;67(5):833-840
pubmed: 30593542
BMC Cancer. 2019 Feb 26;19(1):177
pubmed: 30808336
Histochem Cell Biol. 1995 Feb;103(2):147-56
pubmed: 7634154
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9
pubmed: 9326641